OKYO Pharma remains committed to addressing this significant unmet need and advancing urcosimod through further development. The Company plans confirmatory studies to validate these encouraging ...

Pfizer on Tuesday said the randomized Phase 2 study met its primary endpoint, showing a 40% reduction in the risk of disease progression or death with a manageable safety profile.

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results.

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...